Dupixent and Narrowband UVB for Atopic Dermatitis

• Status: Not yet recruiting
• Trial end date: 2024-03-01
• Target enrollment: 0
• Participant gender: All

Summary

24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Psoriasis Treatment Center of Central New Jersey
• Collaborator: Regeneron Pharmaceuticals

Criteria

Inclusion Criteria:

• Male or female adult ≥ 18 years of age;

• Diagnosis of moderate to severe atopic dermatitis as defined at baseline by:

• EASI score of 16 or greater,

• IGA score of 3 or greater

• BSA of 10% or greater,

Exclusion Criteria:

• Subjects with previous exposure to dupilumab.

• Known or suspected hypersensitivity to dupilumab or any of its excipients.

• History of photosensitivity.